Association of Regulatory Factor X 6 gene (rs339331) polymorphism with Prostate Cancer: A case-control study from South India

Swarnalatha Daram¹ , Subhadra Poornima² , Syeda Zubeda³ , Akhilesh P⁴ , Ayyala V⁵ , Srinadh B⁶ , Shailaja P⁷ , Sandhya A⁸ , Ramakrishna D⁹ , Q Hasan¹⁰

Section:Research Paper, Product Type: Isroset-Journal
Vol.6 , Issue.3 , pp.114-118, Jun-2019

CrossRef-DOI:   https://doi.org/10.26438/ijsrbs/v6i3.114118

Online published on Jun 30, 2019

Copyright © Swarnalatha Daram, Subhadra Poornima, Syeda Zubeda, Akhilesh P, Ayyala V, Srinadh B, Shailaja P, Sandhya A, Ramakrishna D, Q Hasan . This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 

View this paper at   Google Scholar | DPI Digital Library

XML View     PDF Download

How to Cite this Paper

489 Views    264 Downloads    128 Downloads

Abstract :
Prostate Cancer (PCA) is a heterogeneous disease which exhibits clinical variability, morphological differences and molecular marker diversity. Currently, Prostate specific antigen (PSA) evaluation is the only clinically relevant non-invasive marker for PCA screening. A number of genome wide association studies (GWAS) have identified many susceptibility markers for PCA, one of which is a single nucleotide polymorphism (SNP) rs339331, in Regulatory Factor X 6 (RFX6) gene. The present study evaluated this polymorphism g.16677T>C of RFX6 gene, in PCA, benign prostate hyperplasia (BPH) and controls by PCR using specifically designed primers, followed by restriction digestion. Results show that the frequency of ‘C’ allele is 0.74 in PCA and 0.20 in BPH, which is lower than the frequency in controls, which is 0.35. The ‘C’ allele of RFX6 genotype is significantly associated with PCA (P<0.05). This is the first case-control study from India which shows an association of ‘C’ allele of RFX6 gene g.16677T>C polymorphism with high risk of developing PCA and a potential to use it as a biomarker for identifying men at risk of developing PCA.

Key-Words / Index Term :
Benign prostate hyperplasia, genome wide association studies, gene polymorphism, prostate specific antigen

References :
[1] P. Rawla. “Epidemiology of Prostate Cancer”. World Journal of Oncology. Vol. 10(2), pp. 63-89, 2019.
[2] T. Saika, N. Miura, T. Fukumoto, Y. Yanagihara, Y. Miyauchi, T. Kikugawa. “Role of robot‐assisted radical prostatectomy in locally advanced prostate cancer”. International Journal of Urology, Vol. 25(1), pp.30-35, 2018.
[3] F. Bray, J. Ferlay, I. Soerjomataram, RL. Siegel, LA. Torre, A. Jemal. “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. CA: a cancer journal for clinicians, vol: 68(6), pp. 394-424, 2018.
[4] RL Siegel, KD Miller, A. Jemal. “Cancer statistics, 2019”. CA: a cancer journal for clinicians, vol: 69(1), pp. 7-34, 2019.
[5] OP. Singh, V. Yogi, P. Redhu, HU Ghori, A. Pareek, N. Lal. “Role of serum prostate-specific antigen as predictor for bone metastases in newly diagnosed prostate cancer”. Journal of cancer research and therapeutics, Vol.1;15(8), pp.39-41, 2019.
[6] A. Mathew, PS. George, KM JK, D. Vasudevan, FV. James. “Transition of cancer in populations in India”. Cancer epidemiology, Vol.1;58, pp.111-120, 2019.
[7] ME. Rezaee, CE. Ward, BD. Odom, M. Pollock. “Prostate cancer screening practices and diagnoses in patients age 50 and older, Southeastern Michigan, pre/post 2012”. Preventive medicine. Vol.1;82, pp.73-76, 2016.
[8] SV. Carlsson, H. Lilja. “Perspective on Prostate Cancer Screening”. Clinical chemistry, Vol. 1;65(1) pp.24-27, 2019.
[9] S Harrison, K. Tilling, EL. Turner, JA Lane, A Simpkin, M. Davis, J. Donovan, FC. Hamdy, DE. Neal, RM Martin. “Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful?”. Cancer Causes & Control, Vol. 1;27(12), pp.1465-1474, 2016.
[10] FM. Schumacher, AA Al Olama, SI. Berndt, S Benlloch, M Ahmed, EJ Saunders, T Dadaev, D Leongamornlert, E Anokian, C Cieza-Borrella, C. Goh. “Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci”. Nature genetics. Vol.50(7), pp.928, 2018.
[11] Al Olama AA, Z Kote-Jarai, SI Berndt, DV Conti, F Schumacher, Y Han, S Benlloch, DJ Hazelett, Z Wang, E Saunders, D. Leongamornlert. “A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer”. Nature genetics, Vol.46(10), pp.1103, 2014.
[12] NN Wang, Xu Y, K Yang, D Wei, YG Zhang, M Liu, XH Shi, SY Liang, L Sun, XQ Zhu, YG Yang. “Susceptibility loci associations with prostate cancer risk in northern Chinese men”. Asian Pacific Journal of Cancer Prevention, Vol.14(5), pp.3075-3078, 2013.
[13] Q Huang, T Whitington, P Gao, JF Lindberg, Y Yang, J Sun, MR Väisänen, R Szulkin, M Annala, J Yan, LA Egevad. “A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding”. Nature genetics, Vol.46(2), pp.126, 2014.
[14] IG Mills. “HOXB13, RFX6 and prostate cancer risk”. Nature genetics, Vol.46(2), pp.94, 2014.
[15] S Jung, H Jin, RV Davuluri. “Identification of candidate regulatory SNPs by integrative analysis for prostate cancer genome data”. In Proceedings of the 6th ACM Conference on Bioinformatics, Computational Biology and Health Informatics pp. 278-285, 2015.
[16] Li XH, Xu Y, K Yang, JJ Shi, X Zhang, F Yang, H Yuan, X Zhu, YH Zhang, JY Wang, Z Yang. “Association of THADA, FOXP4, GPRC6A/RFX6 genes and 8q24 risk alleles with prostate cancer in Northern Chinese men”. Journal of BU ON.: official journal of the Balkan Union of Oncology. Vol.20(5), pp.1223-1228, 2015.
[17] S. Poornima, K Subramanyam, IA Khan, Q Hasan. “The insertion and deletion (I28005D) polymorphism of the angiotensin I converting enzyme gene is a risk factor for osteoarthritis in an Asian Indian population”. Journal of the Renin-Angiotensin-Aldosterone System, Vol.16(4):1281-1287, 2015.
[18] M Darooei, F Khan, M Rehan, S. Zubeda, E Jeyashanker, S Annapurna, A Shah, S Maddali, Q Hasan. “MED12 somatic mutations encompassing exon 2 associated with benign breast fibroadenomas and not breast carcinoma in Indian women”. Journal of cellular biochemistry, Vol.120(1), pp.182-191, 2019.
[19] IA Khan, S Poornima, P Jahan, P Rao, Q Hasan. “Type 2 diabetes mellitus and the association of candidate genes in Asian Indian population from Hyderabad, India”. Journal of clinical and diagnostic research, Vol (11), pp. GC01-05, 2015.
[20] S. Daram, Z. Syeda, S. Poornima, S. Boppana, S. Prabhala, A. Sandhya, D. Ramakrishna, Q Hasan. “Association of androgen receptor (AR) CAG repeats and cytochrome P450 3a5*3 (cyp3a5*3) gene polymorphisms in men with prostate cancer from south India”. Journal of clinical and diagnostic research, 2019. (Accepted on 1st June 2019).
[21] P Korti, S Prabhala, E Jayashankar, AK Deshpande. “Study of transrectal ultrasound guided biopsies of prostate in correlation with serum prostate specific antigen level”. Indian Journal of Pathology and Oncology, vol: 4(4), pp. 604-610, 2017.
[22] S Lindström, FR Schumacher, D Campa, Albanes, G Andriole, SI Berndt, HB Bueno-de- Mesquita, SJ Chanock, WR Diver, JM Ganziano, SM Gapstur. “Replication of five prostate cancer loci identified in an Asian population results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)”. Cancer Epidemiology and Prevention Biomarkers, vol: 21(1), pp. 212-216, 2012.
[23] M Wang, F Liu, AW Hsing, X Wang, Q Shao, Qi J, Y Ye, Z Wang, H Chen, X Gao, G Wang. “Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: a case–control study in the ChinaPCa consortium”. Carcinogenesis, Vol.23;33(2), pp.356-360, 2011.
[24] R Takata, S Akamatsu, M Kubo, A Takahashi, N Hosono, T Kawaguchi, T Tsunoda, J Inazawa, N Kamatani, O Ogawa , T Fujioka. “Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population”. Nature genetics, Vol.42(9), pp.751, 2010.
[25] R Eeles, C Goh, E Castro, E Bancroft, M Guy, AA Olama Al, D Easton, Z Kote-Jarai. “The genetic epidemiology of prostate cancer and its clinical implications”. Nature reviews Urology, Vol.11(1), pp.18, 2014.
[26] S Aftab, L Semenec, JS Chu, N Chen. “Identification and characterization of novel human tissue-specific RFX transcription factors. BMC evolutionary biology”, Vol.8(1), pp.226-237, 2008.
[27] S Bhatlekar, JZ Fields, BM Boman. “HOX genes and their role in the development of human cancers. Journal of molecular medicine”, Vol.1;92(8), pp.811-823, 2014.
[28] D Sugiaman-Trapman, M Vitezic, EM Jouhilahti, A Mathelier, G Lauter, S Misra, CO Daub, J Kere, P Swoboda. “Characterization of the human RFX transcription factor family by regulatory and target gene analysis”. BMC genomics, Vol.19(1), pp.181-196, 2018.
[29] QZ Long, YF Du, XY Ding, X Li, WB Song ,Y Yang, P Zhang, JP Zhou, XG Liu. “Replication and fine mapping for association of the C2orf43, FOXP4, GPRC6A and RFX6 genes with prostate cancer in the Chinese population”. PLoS One, Vol.7(5), e37866, pp. 1-6, 2012.